Analysis examines the predictive value of hematological markers in recurrent or metastatic head and neck cancer treated with pembrolizumab, highlighting ongoing clinical uncertainty.
The predictive role of hematological markers in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with pembrolizumab remains unclear.
No takes yet. Share an insight, caveat, or question.
Hagiwara et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: